Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

YKL-40 in pediatric asthma, MUC5B promoter polymorphism in idiopathic pulmonary fibrosis, and esmolol in septic shock.

Kulkarni HS, Guzy RD, McEvoy C.

Am J Respir Crit Care Med. 2014 May 1;189(9):1138-40. doi: 10.1164/rccm.201312-2253RR. No abstract available.

PMID:
24787067
2.

The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma.

Konradsen JR, James A, Nordlund B, Reinius LE, Söderhäll C, Melén E, Wheelock AM, Lödrup Carlsen KC, Lidegran M, Verhoek M, Boot RG, Dahlén B, Dahlén SE, Hedlin G.

J Allergy Clin Immunol. 2013 Aug;132(2):328-35.e5. doi: 10.1016/j.jaci.2013.03.003. Epub 2013 Apr 26. Erratum in: J Allergy Clin Immunol. 2013 Nov;132(5):1259. Wheelock, Asa [corrected to Wheelock, Asa M].

PMID:
23628340
3.

Is there a role for β-blockade in septic shock?

Pinsky MR.

JAMA. 2013 Oct 23;310(16):1677-8. doi: 10.1001/jama.2013.278478. No abstract available.

PMID:
24108438
4.

Should β-blockers be used in septic shock?

Lira A, Pinsky MR.

Crit Care. 2014 May 19;18(3):304. doi: 10.1186/cc13878. No abstract available.

5.

Short-acting β-blocker administration in patients with septic shock.

Lin GM.

JAMA. 2014 Feb 19;311(7):737. doi: 10.1001/jama.2014.312. No abstract available.

PMID:
24549559
6.

Short-acting β-blocker administration in patients with septic shock.

Bouglé A, Mira JP.

JAMA. 2014 Feb 19;311(7):736-7. doi: 10.1001/jama.2014.318. No abstract available.

PMID:
24549558
7.

Short-acting β-blocker administration in patients with septic shock.

Sanfilippo F, Santonocito C, Maybauer MO.

JAMA. 2014 Feb 19;311(7):736. doi: 10.1001/jama.2014.315. No abstract available.

PMID:
24549557
8.

Short-acting β-blocker administration in patients with septic shock.

Cortés DO, Taccone FS, Vincent JL.

JAMA. 2014 Feb 19;311(7):735-6. doi: 10.1001/jama.2014.324. No abstract available.

PMID:
24549556
9.

Short-acting β-blocker administration in patients with septic shock--reply.

Morelli A, Ertmer C, Singer M.

JAMA. 2014 Feb 19;311(7):737-8. doi: 10.1001/jama.2014.327. No abstract available.

PMID:
24549560
10.

MUC5B promoter polymorphism and pulmonary fibrosis.

Burch LH.

N Engl J Med. 2011 Jul 14;365(2):178; author reply 178-9. doi: 10.1056/NEJMc1105707#SA2. No abstract available.

PMID:
21751916
11.

MUC5B promoter polymorphism and pulmonary fibrosis.

Zhang GY, Liao T, Gao WY.

N Engl J Med. 2011 Jul 14;365(2):178; author reply 178-9. doi: 10.1056/NEJMc1105707#SA1. No abstract available.

PMID:
21751917
12.

A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis.

Zhang Y, Noth I, Garcia JG, Kaminski N.

N Engl J Med. 2011 Apr 21;364(16):1576-7. doi: 10.1056/NEJMc1013504. No abstract available.

13.

Esmolol for septic shock: more than just heart rate control?

Orbegozo Cortes D, Njimi H, Dell'Anna AM, Taccone FS.

Minerva Anestesiol. 2014 Feb;80(2):254-8.

14.

Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis.

Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, Silveira LJ, Lindell KO, Steele MP, Loyd JE, Gibson KF, Seibold MA, Brown KK, Talbert JL, Markin C, Kossen K, Seiwert SD, Murphy E, Noth I, Schwarz MI, Kaminski N, Schwartz DA.

JAMA. 2013 Jun 5;309(21):2232-9. doi: 10.1001/jama.2013.5827.

15.

MUC5B: a good target for future therapy in pulmonary fibrosis?

Mahida R, Turner AM.

Thorax. 2013 May;68(5):401. doi: 10.1136/thoraxjnl-2012-202957. Epub 2013 Jan 17. No abstract available.

PMID:
23329274
16.

A common MUC5B promoter polymorphism and pulmonary fibrosis.

Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W, Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA.

N Engl J Med. 2011 Apr 21;364(16):1503-12. doi: 10.1056/NEJMoa1013660.

17.

Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis.

Stock CJ, Sato H, Fonseca C, Banya WA, Molyneaux PL, Adamali H, Russell AM, Denton CP, Abraham DJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Lindahl GE, Renzoni EA.

Thorax. 2013 May;68(5):436-41. doi: 10.1136/thoraxjnl-2012-201786. Epub 2013 Jan 15.

PMID:
23321605
18.

MUC5B Promoter Variant rs35705950 Affects MUC5B Expression in the Distal Airways in Idiopathic Pulmonary Fibrosis.

Nakano Y, Yang IV, Walts AD, Watson AM, Helling BA, Fletcher AA, Lara AR, Schwarz MI, Evans CM, Schwartz DA.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):464-6. doi: 10.1164/rccm.201509-1872LE. No abstract available.

PMID:
26871673
19.

Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. A letter to the authors.

Zante B, Wirtz S.

Wien Klin Wochenschr. 2013 Jan;125(1-2):54-5. doi: 10.1007/s00508-012-0305-z. Epub 2012 Dec 6. No abstract available.

PMID:
23224411
20.

Mucking around in the Genome: MUC5B in Idiopathic Pulmonary Fibrosis.

Kolb M, White ES, Gauldie J.

Am J Respir Crit Care Med. 2016 Feb 15;193(4):355-7. doi: 10.1164/rccm.201512-2360ED. No abstract available.

PMID:
26871671
Items per page

Supplemental Content

Write to the Help Desk